Current therapy of multiple sclerosis
Katedra i Klinika Neurologii UM w Lublinie 
Correspondence to: Katedra i Klinika Neurologii UM w Lublinie, ul. Jaczewskiego 8, 20-554 Lublin, tel.: 081 724 47 20
Aktualn Neurol 2009, 9 (2), p. 126-131

Multiple sclerosis (MS) is an autoimmune disease of the nervous system leading to irreversible disability. The currently used therapies in MS include treatment of relapse, disease-modifying therapies and symptomatic therapy. Steroid treatment is used for therapy of relapse. For disease-modifying therapies three different interferon beta products (IFN), glatiramer acetate (GA), natalizumab and mitoxantrone are approved. All those agents significantly reduce disease activity and delay the increase of disability in relapsing-remitting MS. The highest efficacy for IFN was shown in a very early phase of disease. Natalizumab represents the second-line therapy and is used for the ineffectiveness of IFN or GA treatment, in particular in the MS with frequent relapses. Mitoxantrone is approved for reducing neurologic disability and/or the frequency of clinical relapses in patients with worsening relapsing-remitting or secondary progressive MS. Symptomatic treatment includes spasticity, pain, fatigue, bladder dysfunction, depression and cognitive impairment therapies.

Keywords: multiple sclerosis, treatment of relapse, immunomodulatory therapy, immunosuppressive therapy, symptomatic treatment